PMID: 11322350Apr 27, 2001Paper

Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study

Mayo Clinic Proceedings
Rodney A AppellOveractive Bladder: Judging Effective Control and Treatment Study Group

Abstract

To compare the efficacy and tolerability of extended-release oxybutynin chloride and tolterodine tartrate at 12 weeks in participants with overactive bladder. The OBJECT (Overactive Bladder: Judging Effective Control and Treatment) study was a prospective, randomized, double-blind, parallel-group study conducted between March and October 2000 at 37 US study sites. Participants who had between 7 and 50 episodes of urge incontinence per week and 10 or more voids in 24 hours received extended-release oxybutynin, 10 mg/d, or tolterodine, 2 mg twice daily. The outcome measures were the number of episodes of urge incontinence, total incontinence, and micturition frequency at 12 weeks adjusted for baseline. A total of 315 women and 63 men were randomized and treated, and 332 participants (276 women, 56 men) completed the study. At the end of the study, extended-release oxybutynin was significantly more effective than tolterodine in each of the main outcome measures: weekly urge incontinence (P=.03), total incontinence (P=.02), and micturition frequency episodes (P=.02) adjusted for baseline. Both drugs improved symptoms of overactive bladder significantly from baseline to the end of the study as assessed by the 3 main outcome measures...Continue Reading

References

Mar 24, 1998·Urology·T H Wagner, T W Hu
Oct 16, 2001·The Journal of Clinical Endocrinology and Metabolism·UNKNOWN Advisory Panel on Testosterone Replacement in Men
Feb 13, 2002·Kennedy Institute of Ethics Journal·UNKNOWN National Reference Center for Bioethics Literature

❮ Previous
Next ❯

Citations

Jan 14, 2005·International Urogynecology Journal and Pelvic Floor Dysfunction·Mesfer Al-Shahrani, Danny Lovatsis
Dec 20, 2005·International Urogynecology Journal and Pelvic Floor Dysfunction·Roger R Dmochowski
Sep 15, 2012·International Urogynecology Journal·Kelly Jirschele, Peter K Sand
Sep 6, 2005·International Urology and Nephrology·Robert B ArmstrongKenneth M Peters
Oct 2, 2002·Current Urology Reports·H Henry LaiRodney A Appell
Nov 12, 2002·Current Urology Reports·David R Staskin
Nov 12, 2002·Current Urology Reports·Roger R Dmochowski, David R Staskin
Nov 19, 2003·Current Urology Reports·Scott A MacDiarmid
Oct 22, 2005·Current Urology Reports·David R StaskinAlan J Wein
Nov 29, 2007·Current Urology Reports·Adam P Klausner, William D Steers
Jul 24, 2012·Current Urology Reports·Philip E V Van Kerrebroeck
Nov 17, 2001·Urology·K M Peters, R R Huang
Feb 14, 2002·Australian Family Physician
Oct 24, 2002·The American Journal of Nursing·Diane Kaschak Newman, Donna Giovannini
Feb 28, 2002·Clinical Obstetrics and Gynecology·Tracy Washington Cannon, Michael B Chancellor
Mar 17, 2004·Clinical Obstetrics and Gynecology·Ingrid E Nygaard, Karl J Kreder
Jul 11, 2007·Postgraduate Medical Journal·Sushma SrikrishnaMaria Vella
Jun 21, 2011·Advances in Urology·Anastasios Athanasopoulos, Konstantinos Giannitsas
Nov 11, 2003·Clinical Pharmacokinetics·David R P Guay
Mar 22, 2006·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·J Mark Ruscin
Dec 21, 2004·Der Internist·M OelkeU Jonas
Sep 5, 2015·Cutaneous and Ocular Toxicology·Damla Erginturk AcarSabri Cavkaytar
Jan 23, 2016·Expert Opinion on Pharmacotherapy·Helena Burden, Paul Abrams
Feb 7, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Konstantinos Giannitsas, Anastasios Athanasopoulos
Aug 16, 2003·British Journal of Clinical Pharmacology·C BroadhurstJ K Dhesi
Sep 17, 2003·Oral Diseases·C Scully
Apr 21, 2004·Neurourology and Urodynamics·Roland C D EnglandRuth A Elliott
Jun 7, 2011·Annals of Medicine·Ariana L Smith, Alan J Wein
Oct 18, 2005·BJU International·Roger R DmochowskiG Willy Davila
Feb 21, 2009·International Journal of Urology : Official Journal of the Japanese Urological Association·Osamu YamaguchiUNKNOWN Neurogenic Bladder Society

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.